The Zenas BioPharma, Inc. (Nasdaq: ZBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zenas is a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, and its filings document key aspects of its business, including stock exchange listing details, financing arrangements, licensing agreements and clinical development updates.
Recent Form 8-K filings describe material events such as the revenue participation and funding agreement with Royalty Pharma related to obexelimab, under which Royalty Pharma will provide up to $300 million in consideration in exchange for specified royalty and revenue participation rights. Other 8-Ks detail the license agreement with InnoCare Pharma granting Zenas exclusive rights to develop, manufacture and commercialize orelabrutinib in the multiple sclerosis field globally and non-oncology indications outside certain territories, as well as rights to ZB021 and ZB022. Additional current reports cover private placement financings, adoption of the 2026 Inducement Plan for equity awards, and press releases furnishing quarterly financial results.
Through this page, users can review how Zenas reports its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ZBIO, and the terms of material definitive agreements that shape its capital structure and pipeline strategy. Filings linked here include exhibits such as inducement equity plans, option and restricted stock unit agreements, subscription and registration rights agreements, and revenue participation contracts, which provide further detail on governance and compensation frameworks.
Stock Titan enhances these documents with AI-powered summaries that explain the significance of each filing in clear language. As new 8-Ks, 10-Qs, 10-Ks and other forms become available on EDGAR, they are incorporated so investors can quickly see how developments in obexelimab, orelabrutinib, ZB021 and ZB022, as well as financing and licensing transactions, are reflected in Zenas BioPharma’s official regulatory record.
Zenas BioPharma, Inc. (ZBIO) is reported to have 1,000,000 common shares beneficially owned by Xencor, Inc., equal to 1.5% of the class. Xencor reported sole voting and dispositive power over 1,000,000 shares, with shared voting and dispositive power of zero. The percentage calculation uses 65,176,723 Zenas common shares outstanding as of July 31, 2026; the reported ownership is 5% or less.
Zenas BioPharma, Inc. reported third-quarter 2026 revenue of $10.0 million and a net loss of $108.9 million, compared with no revenue and a $51.5 million net loss a year earlier. Revenue included a $10.0 million development and regulatory milestone payment from Bristol-Myers Squibb tied to the first regulatory approval application filing in Japan. Research and development expense was $58.5 million, and acquired in-process research and development expense was $27.5 million.
For the nine months ended September 30, 2026, Zenas recorded a net loss of $301.4 million and used $190.4 million in operating activities, versus $137.3 million and $119.9 million, respectively, in 2025. Cash, cash equivalents and investments totaled $647.1 million as of September 30, and management expected that balance to fund operating and capital expenditures for at least twelve months from issuance of the statements. Management also expects operating losses and negative operating cash flows to continue for the foreseeable future. At quarter-end, outstanding principal was $75.0 million on the senior secured term loan and $230.0 million on convertible senior notes.
Zenas BioPharma, Inc. reported $10 million in license and collaboration revenue for the quarter ended September 30, 2026; the comparable 2025 table entry is “—”. Net loss was $108.923 million, versus $51.499 million, and net loss per share was $1.65, versus $1.22. Research and development expense was $58.474 million, compared with $34.402 million.
Cash, cash equivalents and investments totaled $647.082 million as of September 30, 2026, compared with $360.464 million as of December 31, 2025. At September 30, total liabilities were $462.908 million; the balance sheet listed a $76.118 million senior secured term loan, net, and $223.239 million of convertible senior notes, net. FDA set a May 27, 2027 PDUFA target action date after accepting obexelimab’s BLA in the second quarter of 2026; Zenas also submitted an MAA to the EMA for IgG4-RD. Phase 2 SunStone SLE topline results are on track for fourth quarter 2026, while initial Phase 1 ZB021 data are expected in fourth quarter 2026. Jerald Korn was appointed Chief Legal and Strategy Officer.
Zenas BioPharma, Inc. (ZBIO) was the issuer in a Schedule 13G reporting BlackRock, Inc.’s beneficial ownership of 3,287,021 common shares, equal to 5.0% of the class. BlackRock reported sole voting power over 3,226,537 shares and sole dispositive power over 3,287,021 shares, with no shared voting or dispositive power. It stated that various persons may receive dividends or sale proceeds from the shares, but no one person’s interest exceeds 5% of the total outstanding common shares.
Zenas BioPharma, Inc. (ZBIO) announced a presentation of new obexelimab data in IgG4-related disease at the 6th International Symposium on IgG4-Related Disease. In the Phase 3 INDIGO open-label extension, participants who completed the 52-week randomized, controlled period could enter and receive 250 mg obexelimab subcutaneously once weekly. The extension evaluated longer-term flare protection and safety.
Other INDIGO analyses evaluated glucocorticoid-associated toxicity and vaccine immune responses during a planned treatment-free window, including preservation of pre-existing influenza and SARS-CoV-2 immunity after long-term obexelimab exposure. Zenas says obexelimab has been evaluated in nine clinical trials involving 667 subjects, including INDIGO.
Zenas BioPharma, Inc. (ZBIO) has filed an automatic shelf registration statement on Form S-3 to register the resale of up to 7,000,000 already-issued shares of common stock held by InnoCare Pharma Inc. The company is not offering any shares and will not receive proceeds from these sales; all proceeds go to the selling stockholder, while Zenas bears the registration costs.
The shares were issued to InnoCare under a broader strategic relationship, including an October 2025 license agreement for orelabrutinib and early-stage candidates ZB021 and ZB022, and related subscription and registration rights agreements. Zenas paid $35.0 million in upfront cash and issued 5,000,000 shares initially, then upon an August 2026 regulatory milestone became obligated to pay an additional $25.0 million and issue 2,000,000 more shares. InnoCare’s transfers are contractually volume-limited after an initial lock-up ending October 7, 2026.
Zenas highlights its immunology and inflammation pipeline led by obexelimab, which met the primary and key secondary endpoints in a Phase 3 IgG4‑RD trial and has a BLA accepted by the FDA with a PDUFA target date of May 27, 2027. The filing confirms Zenas’ status as a well-known seasoned issuer and outlines extensive forward‑looking risks tied to clinical progress, regulatory outcomes, financing needs and market conditions.
For Zenas BioPharma, Inc. (ZBIO), a group of Wellington investment entities filed a Schedule 13G reporting passive beneficial ownership of Zenas common stock. They report aggregate beneficial ownership of 6,566,134 shares of common stock, representing 10.07% of the outstanding class.
The Wellington entities report no sole voting or dispositive power, but shared voting power over 6,308,474 shares and shared dispositive power over 6,566,134 shares, held in client accounts advised by various Wellington investment advisers. The filing notes that clients, including Vanguard Health Care Fund, have rights to dividends or sale proceeds, but no individual client is known to hold more than five percent of the class.
Zenas BioPharma, Inc. (ZBIO) reports that InnoCare Pharma Inc. has filed an initial statement of beneficial ownership as a ten percent owner. The filing lists 7,000,000 shares of Common Stock held directly as of August 26, 2026, with no specific acquisition or disposal transaction reported.
Zenas BioPharma, Inc. (ZBIO) received an amended Schedule 13G/A filing in which InnoCare Pharma Inc., Ocean Prominent Limited and InnoCare Pharma Limited report a passive ownership stake. The reporting group states beneficial ownership of 7,000,000 shares of Zenas BioPharma common stock held directly by InnoCare Pharma Inc., a wholly owned subsidiary of Ocean Prominent Limited, which is wholly owned by InnoCare Pharma Limited.
The stake represents 10.4% of Zenas BioPharma’s common stock, calculated from 65,176,723 shares outstanding as of July 31, 2026 plus 2,000,000 shares issued to InnoCare Pharma Inc. in a milestone-triggered private placement that closed on August 31, 2026. The reporting persons indicate shared voting and dispositive power over the 7,000,000 shares and disclaim status as a group for this amendment.
Zenas BioPharma, Inc. (ZBIO) reported that director Christy J. Oliger received a grant of 37,000 stock options on September 1, 2026. The options have an exercise price of $31.98 per share and expire on August 31, 2036. The award vests in equal annual installments over three years beginning September 1, 2027, subject to continued service, and no Rule 10b5-1 trading plan is reported.